Compare BGLC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGLC | IMNN |
|---|---|---|
| Founded | 2017 | 1982 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 11.0M |
| IPO Year | 2019 | 2000 |
| Metric | BGLC | IMNN |
|---|---|---|
| Price | $2.28 | $3.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | 8.7K | ★ 22.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.78 | 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,510,646.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.37 |
| 52 Week High | $15.19 | $9.32 |
| Indicator | BGLC | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 45.08 |
| Support Level | $1.92 | $3.03 |
| Resistance Level | $2.73 | $4.26 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 13.11 | 27.36 |
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).